Salt AI, based in Los Angeles, secured $10 million in new funding, led by Morpheus Ventures. This investment will expand the company's contextual AI platform for life sciences and health tech.
Expanding Contextual AI for Healthcare Innovation
Salt AI develops a visual-first platform. It transforms complex artificial intelligence models into production-ready workflows for biopharma and healthcare.
The platform currently supports drug discovery, clinical development, and revenue cycle management. It also aids intelligent data navigation and enterprise operations. Salt AI's technology unpacks enterprise AI applications for pharmaceutical and biotech organizations. Competitors like Palantir and Databricks also offer data integration solutions.
The Salt Matrix, a core component, offers sector-specific data connectors and models. This enables rapid AI workflow construction using intuitive drag-and-drop tools. Salt AI delivers value through visual collaboration, ensuring speed to value. It also provides trusted compliance and scale for proprietary data. The platform integrates seamlessly with cloud computing environments.
Struck Capital, Marbruck Investments, and CoreWeave also participated in the Salt AI funding round. The capital from this Salt AI funding round accelerates the delivery and impact of their solutions. Tempus AI also operates in the life sciences data space.
The company's platform has already accelerated breakthroughs at the Ellison Medical Institute. It significantly speeds up drug discovery. This advancement allows for the design and analysis of thousands of compounds.
Salt AI's approach emphasizes ensembles of models working in synergy. This drives healthcare innovation forward.
Salt AI aims to redefine AI support for discovery and care at scale.
